{"organizations": [], "uuid": "6af6f9ca0d0a91b72beb846620fa5eac9a9c1115", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180306.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-promis-neurosciences-lead-product/brief-promis-neurosciences-lead-product-candidate-for-alzheimers-disease-shows-potential-for-improved-therapeutic-potency-idUSFWN1QO0D9", "country": "US", "domain_rank": 408, "title": "BRIEF-ProMIS Neurosciences Lead Product Candidate For Alzheimer's Disease Shows Potential For Improved Therapeutic Potency", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.985, "site_type": "news", "published": "2018-03-06T20:43:00.000+02:00", "replies_count": 0, "uuid": "6af6f9ca0d0a91b72beb846620fa5eac9a9c1115"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-promis-neurosciences-lead-product/brief-promis-neurosciences-lead-product-candidate-for-alzheimers-disease-shows-potential-for-improved-therapeutic-potency-idUSFWN1QO0D9", "ord_in_thread": 0, "title": "BRIEF-ProMIS Neurosciences Lead Product Candidate For Alzheimer's Disease Shows Potential For Improved Therapeutic Potency", "locations": [], "entities": {"persons": [{"name": "eimer", "sentiment": "none"}], "locations": [], "organizations": [{"name": "promis neurosciences inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6 (Reuters) - ProMIS Neurosciences Inc:\n* PROMIS NEUROSCIENCES LEAD PRODUCT CANDIDATE FOR ALZHEIMERâ€™S DISEASE SHOWS POTENTIAL FOR IMPROVED THERAPEUTIC POTENCY VERSUS OTHER AMYLOID BETA-DIRECTED ANTIBODIES\n* PROMIS NEUROSCIENCES INC - PMN310 SHOWED SIMILAR ABILITY TO CROSS BLOOD BRAIN BARRIER AND PENETRATE CENTRAL NERVOUS SYSTEM COMPARED TO ADUCANUMAB Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-06T20:43:00.000+02:00", "crawled": "2018-03-07T19:46:32.043+02:00", "highlightTitle": ""}